Clinical study Assessing SSR126517E Injections Once-weekly in Pulmonary Embolism therapeutic Approach (2010)


Treatment of acute pulmonary embolism (PE)

Close this section


To assess the non-inferiority of idrabiotaparinux to warfarin in patients with acute symptomatic PE

Close this section

Trial design

Randomized, double-blind, double-dummy, non-inferiority phase III study
Active treatment: enoxaparin 1.0 mg/kg s.c. twice daily for 5–10 days followed by subcutaneous idrabiotaparinux 3.0 mg once weekly and placebo tablets (n=1599)
Control treatment: enoxaparin 1.0 mg/kg s.c. twice daily for 5–10 days followed by adjusted-dose warfarin (target INR 2.0–3.0) plus weekly placebo injections (n=1603)
Both regimens lasted 3 months or 6 months dependent on clinical presentation. 79% of the patients continued study therapy for 6 months (n=1269 in the enoxaparin-idrabiotaparinux group and n=1267 in the enoxaparin-warfarin group)

Close this section


Primary efficacy endpoint: symptomatic recurrent VTE, defined as either recurrent PE or DVT within 99 days of randomization
Secondary efficacy endpoint: symptomatic recurrent VTE within 190 days in patients assigned to receive treatment for 6 months
Primary safety endpoint: clinically relevant bleeding (major or non-major) and death from all causes

Close this section

Trial participants

3202 patients aged 18–96 years with objectively confirmed, symptomatic, acute PE

Close this section


Efficacy outcome: At day 99, 2.1% (34 of 1599) patients randomly allocated to receive enoxaparin-idrabiotaparinux and 2.7% (43 of 1603) patients given enoxaparin-warfarin had recurrent venous thromboembolic events (p=0.0001 for non-inferiority). Incidence of recurrent VTE also did not differ significantly between treatment groups at day 190 for patients assigned to receive 6 months’ treatment: 2.3% with enoxaparin-idrabiotaparinux vs. 2.8% with enoxaparin-warfarin (p=0.0001 for non-inferiority). However, the protective effect of idrabiotaparinux remained present for additional 6 months after treatment cessation, whereas there was an almost immediate and constant increase over time of recurrent VTE after cessation of warfarin. During follow-up after planned end of study drug intake (i.e., 99 days or 190 days), there were only 9 recurrences in patients originally assigned to receive idrabiotaparinux and 47 in those assigned to receive warfarin in one year
Safety outcome: By day 99, more patients had clinically relevant bleeding in the enoxaparin-warfarin group (4,5%) than in the enoxaparin-idrabiotaparinux group (6.6%) (p=0.0098 for superiority). However, this difference did not persist to 190 days in patients assigned to receive 6 months’ treatment (6.6% vs. 8,1%; p=0.17 for superiority)

Close this section


Efficacy: In patients with symptomatic acute pulmonary embolism treated with enoxaparin for 5–10 days, once weekly subcutaneous idrabiotaparinux was as effective as adjusted daily doses of warfarin for long-term treatment and prevention of VTE. The indirect factor Xa inhibitor showed a protective effect up to 12 months
Safety: Idrabiotaparinux was associated with less frequent bleeding than was treatment with warfarin

Close this section


Büller HR, Gallus AS, Pillion G, Prins MH, Raskob GE, for the CASSIOPEA Investigators. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2012;379:123-129

Close this section

Corresponding author

Prof. Harry R. Büller, Department of Vascular Medicine, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands, e-mail:

Close this section

Back To List

Recommend pageBack to top